Aubagio

October 30, 2017October 31, 2017

#MSParis2017 – Aubagio Can Help Slow Progression to an MS Diagnosis, Researcher Says

News

Aubagio (teriflunomide) can help to delay first clinical signs of multiple sclerosis (MS) from progressing to a definite diagnosis in a person, and treatment should likely begin ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – MS Therapy Aubagio Does Not Appear to Cause Birth Defects, Study Reports

News

Sanofi Genzyme’s multiple sclerosis therapy Aubagio (teriflunomide) does not appear to cause birth defects in humans as it does in laboratory animals, researchers concluded after studying more than ... Read more

October 23, 2017October 24, 2017

#MSParis2017 – Sanofi to Present Long-term Data on Lemtrada and Aubagio Use

News

New data on how Lemtrada and Aubagio perform in a real-world setting will be the focus of Sanofi Genzyme when the company showcases its ... Read more

October 16, 2017October 17, 2017

Multiple Sclerosis Therapy Aubagio May Cause Nail Loss, Researchers Report

News

Aubagio (teriflunomide) may lead to reversible nail loss, researchers at Italy’s University of Bologna reported after reviewing the case of a 55-year-old woman with relapsing-remitting multiple sclerosis. They described ... Read more

August 8, 2017August 8, 2017

TG Therapeutics, FDA Agree on Phase 3 Program to Evaluate Relapsing MS Therapy TG-1101

News

TG Therapeutics and the U.S. Food and Drug Administration (FDA) have agreed on a special protocol assessment for a Phase 3 trial program evaluating TG-1101 (ublituximab) to potentially ... Read more

April 26, 2017April 26, 2017

Sanofi Genzyme to Present New Data on MS Treatments Lemtrada and Aubagio

News

Sanofi Genzyme will present new results on follow-up studies of its products Lemtrada (alemtuzumab) and Aubagio (teriflunomide), both of which have been approved for the treatment ... Read more

April 19, 2017April 19, 2017

Sanofi Genzyme to Discuss Three Multiple Sclerosis Therapies at Boston Event

News

Sanofi Genzyme will discuss three of its multiple sclerosis therapies at the American Academy of Neurology annual meeting in Boston, April 22-28. The presentations will cover two approved treatments ... Read more

November 8, 2016November 8, 2016

Plans by 4 Countries to Subsidize Cost of Newer MS Drugs May Weight on US

News

A cost-effectiveness analysis of reimbursement recommendations for four relatively new multiple sclerosis (MS) treatments made by agencies in four countries — Australia, Canada, Sweden, and the U.K. ... Read more

September 20, 2016September 20, 2016

#ECTRIMS2016 – Sanofi Releases Patients’ Views of Aubagio as Effective Treatment for Relapsing MS

News

Sanofi Genzyme presented positive results from its Phase 4 study into patient-reported assessments of Aubagio (teriflunomide), an approved oral treatment for relapsing forms of multiple sclerosis (RMS). Real-world patient responses ... Read more

August 12, 2016

9 Approved MS Therapies You Should Know About

1. AMPYRA (dalfampridine) Dalfampridine, marketed under the name Ampyra by Acorda Therapeutics in the United States (also referred to as Fampyra in Europe), is an FDA-approved drug ... Read more

July 10, 2016

9 Approved MS Therapies You Should Know About

1. AMPYRA (dalfampridine) Dalfampridine, marketed under the name Ampyra by Acorda Therapeutics in the United States (also referred to as Fampyra in Europe), is an FDA-approved drug ... Read more

July 6, 2016July 6, 2016

ICER Draft Report Evaluating Therapies for RRMS Now Open for Public Comment

News

The Institute of Clinical and Economic Review (ICER) released the early draft of a paper intended to inform a future report evaluating the effectiveness and value of disease-modifying therapies for ... Read more

June 13, 2016June 13, 2016

Genmab to Begin Phase 3 Trials of Ofatumumab to Treat Relapsing Multiple Sclerosis

News

Genmab announced plans to soon begin a Phase 3 clinical trial program assessing the subcutaneous formulation of ofatumumab as a potential treatment for relapsing multiple sclerosis (MS). The company, working in ... Read more

May 23, 2016June 17, 2016

9 Approved MS Therapies You Should Know About

1. AMPYRA (dalfampridine) Dalfampridine, marketed under the name Ampyra by Acorda Therapeutics in the United States (also referred to as Fampyra in Europe), is an FDA-approved drug ... Read more

April 18, 2016April 18, 2016

Sanofi Genzyme Presenting New Data on Its Approved and Investigational Multiple Sclerosis Treatments at AAN

News

Sanofi Genzyme will present new data on its approved multiple sclerosis (MS) treatments — Lemtrada (alemtuzumab) and Aubagio (teriflunomide) — at the 68th annual meeting of the American Academy of Neurology (AAN), taking ... Read more

April 1, 2016April 3, 2016

Study Finds Aubagio Well-tolerated and Efficient in Long-term MS Treatment

News

Researchers at the University of Texas Health Science Center at Houston, in collaboration with various institutions from north America and Europe, found that teriflunomide (Aubagio) is ... Read more

March 21, 2016March 22, 2016

CONy16: Sanofi Genzyme Symposium on MS Therapies Targeting T and B Cells; Exclusive Interview with Lead Researcher

News

Sanofi Genzyme, one of the companies participating in the four-day 10th World Congress on Controversies in Neurology (CONy) in Lisbon, Portugal, that concluded on March 20, 2016, supported several symposiums ... Read more

March 4, 2016May 14, 2016

In ‘Take Action on MS,’ a New Web Series, Actress Madeleine Stowe Tackles Topics of Import to RRMS Patients

News

Genzyme, a specialty care unit of Sanofi, announced that TV and film actress Madeleine Stowe will host its new online series, “Take Action on MS,” focusing on people living with relapsing ... Read more

October 13, 2015September 7, 2016

Insights into Promising MS Therapies at Late Breaking News Session, ECTRIMS 2015

News

A session titled “Late Breaking News” was featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 7-10, ... Read more

October 8, 2015October 8, 2015

Aubagio (Teriflunomide) Slows Brain Atrophy in Patients with Relapsing Multiple Sclerosis

News

Genzyme recently announced results from magnetic resonance imaging (MRI) analysis of participants in the Phase III TEMSO clinical trial showing that Aubagio® (teriflunomide) was able to slow the ... Read more

June 26, 2015June 26, 2015

Health Canada Non-Insured Health Benefits Program Approves AUBAGIO for Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis News, News

Genzyme Canada has announced that Health Canada has approved its 14 mg dose of AUBAGIO as an expedited exception benefit product through the federal health regulator’s ... Read more

May 26, 2015May 26, 2015

AUBAGIO Included in Prince Edward Island Pharmacare

News

Canadian province Prince Edward Island (PEI) has approved the inclusion of Aubagio (teriflunomide) 14 mg in the PEI Pharmacare’s provincial drug formulary. This means that the ... Read more

January 7, 2015January 7, 2015

Nova Scotia First Of Canada’s Atlantic Provinces To Fund Aubagio Treatment For Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis News, News

Canada has one of the world’s highest Multiple Sclerosis (MS) prevalence rates. Some 100,000 Canadians live with the disease, and three people are newly diagnosed each ... Read more

December 26, 2014December 26, 2014

British Columbia Agrees To fund AUBAGIO RRMS Therapy

Multiple Sclerosis News, News

British Columbia’s PharmaCare drug program has announced that it will fund AUBAGIO, a therapy developed by Genzyme for the treatment of multiple sclerosis. AUBAGIO (teriflunomide) 14 mg has been officially added to PharmaCare’s ... Read more

December 2, 2014December 2, 2014

Aubagio for Relapsing-Remitting MS Now Funded in Alberta

News

Genzyme, a Sanofi company with over 30 years of dedication to researching and developing novel treatments for rare and orphan diseases, has just announced the Alberta ... Read more

November 25, 2014November 25, 2014

Province Of Ontario Funds Genzyme’s AUBAGIO For Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis News, News

With 100,000 Canadians living with Multiple Sclerosis (MS), and three people newly diagnosed every day, Canada has one of the highest prevalence rates for the disease ... Read more

October 27, 2014October 27, 2014

Positive Data from Two Key MS Trials Added To Aubagio’s U.S. Label

Multiple Sclerosis News, News

The Food and Drug Administration (FDA) recently accepted the results from Genzyme’s TOWER and TOPIC  clinical trials, which assessed the safety and efficacy of oral, once-daily Aubagio® ... Read more

October 16, 2014July 19, 2016

Revenge Star Madeleine Stowe is the New Face of Multiple Sclerosis

Multiple Sclerosis News, News

Television’s “Queen of Mean,” Revenge‘s Madeleine Stowe, recently opened up about her early memories of her father living with multiple sclerosis (MS), a progressive neurodegenerative disease that, ... Read more

September 9, 2014October 9, 2015

Genzyme’s Aubagio, Lemtrada MS Therapies To Showcase at Conference

Multiple Sclerosis News, News

During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) taking place in Boston between September 10th and 13th, Genzyme, ... Read more